{"id":"combigan","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00981786","NCT01151904","NCT01514734","NCT01217606","NCT00652106","NCT00822055","NCT00824824","NCT02167035","NCT00800540","NCT01446497","NCT00735449","NCT02214680","NCT01241240","NCT01518244","NCT00822081","NCT04296916","NCT00442312","NCT00811850","NCT00651612","NCT01415401","NCT06078592","NCT03235232","NCT00811564","NCT02863705","NCT00621335","NCT02718547","NCT02623023","NCT01987752","NCT01170884","NCT01229462","NCT00706927"],"aliases":["(Combigan®","brimonidine tartrate/timolol maleate ophthalmic solution"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"Combigan","companyId":"mcmaster-university","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"McMaster University","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Combigan","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00981786","phase":"Phase 4","title":"Quality of 24-hour Intraocular Pressure Control Obtained With the Brinzolamide/Timolol Fixed Combination Compared With the Brimonidine/Timolol Fixed Combination When Added to Travoprost Monotherapy in","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","isPivotal":false,"enrollment":51,"indication":"Glaucoma","completionDate":"2010-12"},{"nctId":"NCT01151904","phase":"Phase 4","title":"","status":"TERMINATED","sponsor":"Allergan","isPivotal":false,"enrollment":17,"indication":"Glaucoma, Angle-Closure","completionDate":"2012-02"},{"nctId":"NCT01514734","phase":"Phase 4","title":"Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBI","status":"TERMINATED","sponsor":"Alcon Research","isPivotal":false,"enrollment":9,"indication":"Glaucoma","completionDate":"2012-08"},{"nctId":"NCT01217606","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"Allergan","isPivotal":true,"enrollment":185,"indication":"Glaucoma, Open-Angle, Ocular Hypertension","completionDate":"2015-06"},{"nctId":"NCT00652106","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"Allergan","isPivotal":true,"enrollment":432,"indication":"Glaucoma, Ocular Hypertension","completionDate":"2004-03"},{"nctId":"NCT00822055","phase":"Phase 4","title":"","status":"COMPLETED","sponsor":"Allergan","isPivotal":false,"enrollment":140,"indication":"Open-Angle Glaucoma, Ocular Hypertension","completionDate":"2006-11"},{"nctId":"NCT00824824","phase":"NA","title":"Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","isPivotal":false,"enrollment":21,"indication":"Glaucoma","completionDate":"2012-08"},{"nctId":"NCT02167035","phase":"Phase 4","title":"Pilot Study Comparison of Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in Subjects Currently Treated With Latanoprost For Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Cornerstone Health Care, PA","isPivotal":false,"enrollment":43,"indication":"Glaucoma, Ocular Hypertension","completionDate":"2018-03"},{"nctId":"NCT00800540","phase":"Phase 4","title":"Effects of Topical Hypotensive Drugs on Circadian Ocular Perfusion Pressure and Ocular Blood Flow in Patients With Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Alcon Research","isPivotal":false,"enrollment":35,"indication":"Glaucoma","completionDate":"2012-01"},{"nctId":"NCT01446497","phase":"Phase 4","title":"Randomized, Multicenter, Open-label, Parallel Group Study to Evaluate Efficacy and Safety of Combigan(Brimonidine/Timolol) and 0.5% Timoptic(Timolol) Ophthalmic Solutions in Normal Tension Glaucoma Pa","status":"UNKNOWN","sponsor":"Seoul National University Hospital","isPivotal":false,"enrollment":22,"indication":"Normal Tension Glaucoma","completionDate":"2012-08"},{"nctId":"NCT00735449","phase":"Phase 4","title":"Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects","status":"COMPLETED","sponsor":"Allergan","isPivotal":false,"enrollment":204,"indication":"Glaucoma, Ocular Hypertension","completionDate":"2009-12"},{"nctId":"NCT02214680","phase":"Phase 2","title":"The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter","status":"UNKNOWN","sponsor":"Carmel Medical Center","isPivotal":false,"enrollment":25,"indication":"Healthy","completionDate":"2016-12"},{"nctId":"NCT01241240","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"Allergan","isPivotal":true,"enrollment":192,"indication":"Glaucoma, Open-Angle, Ocular Hypertension","completionDate":"2013-09"},{"nctId":"NCT01518244","phase":"Phase 4","title":"Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBI","status":"COMPLETED","sponsor":"Alcon Research","isPivotal":false,"enrollment":50,"indication":"Glaucoma","completionDate":"2013-02"},{"nctId":"NCT00822081","phase":"Phase 4","title":"","status":"COMPLETED","sponsor":"Bp Consulting, Inc","isPivotal":false,"enrollment":140,"indication":"Open-Angle Glaucoma, Ocular Hypertension","completionDate":"2006-04"},{"nctId":"NCT04296916","phase":"NA","title":"Effect of Medically Lowering Intraocular Pressure in Glaucoma Suspects With High Myopia: A Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","isPivotal":false,"enrollment":264,"indication":"Glaucoma, Suspect, High Myopia","completionDate":"2024-10"},{"nctId":"NCT00442312","phase":"Phase 4","title":"An Open Label,Switch Study of the Safety and Efficacy of Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy in Patient With Glaucoma ","status":"UNKNOWN","sponsor":"Genovate Biotechnology Co., Ltd.,","isPivotal":false,"enrollment":43,"indication":"Glaucoma","completionDate":"2006-11"},{"nctId":"NCT00811850","phase":"Phase 4","title":"","status":"COMPLETED","sponsor":"Allergan","isPivotal":false,"enrollment":15,"indication":"Glaucoma","completionDate":"2009-12"},{"nctId":"NCT00651612","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"Allergan","isPivotal":true,"enrollment":604,"indication":"Glaucoma, Ocular Hypertension","completionDate":"2007-01"},{"nctId":"NCT01415401","phase":"Phase 4","title":"Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Th","status":"COMPLETED","sponsor":"Alcon Research","isPivotal":false,"enrollment":57,"indication":"Glaucoma, Ocular Hypertension","completionDate":"2013-06"},{"nctId":"NCT06078592","phase":"Phase 4","title":"Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN- PLUS® Eye Drops and COMBIGAN® Eye Drops in Glaucoma or Ocular Hypertensive Patients","status":"COMPLETED","sponsor":"CHA University","isPivotal":false,"enrollment":60,"indication":"Glaucoma, Ocular Hypertensive","completionDate":"2022-12-23"},{"nctId":"NCT03235232","phase":"Phase 3","title":"Randomized Clinical Trial to Compare the Efficacy and Safety of BREMEN Eye Drops Versus Combigan in Subjects With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"EMS","isPivotal":true,"enrollment":406,"indication":"Ocular Hypertension, Primary Open-angle Glaucoma","completionDate":"2023-10-31"},{"nctId":"NCT00811564","phase":"Phase 4","title":"","status":"COMPLETED","sponsor":"Allergan","isPivotal":false,"enrollment":148,"indication":"Glaucoma, Ocular Hypertension","completionDate":"2010-01"},{"nctId":"NCT02863705","phase":"Phase 4","title":"A 12-Month, Phase 4, Open Label, Multicenter, Trial to Assess the Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)","status":"COMPLETED","sponsor":"Allergan","isPivotal":false,"enrollment":118,"indication":"Glaucoma, Open-Angle, Normal Tension Glaucoma","completionDate":"2018-07-25"},{"nctId":"NCT00621335","phase":"N/A","title":"A 12- Week Investigator Masked, Parallel Comparison of Tolerability of Combigan and Cosopt in the Treatment of Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"DBYAN Medicine Professional Corporation","isPivotal":false,"enrollment":64,"indication":"Open Angle Glaucoma, Ocular Hypertension","completionDate":"2008-02"},{"nctId":"NCT02718547","phase":"NA","title":"The Effect of Reducing the Intraocular Pressure by Using Alphagan Drops and Macular Edema in Patients With Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Meir Medical Center","isPivotal":false,"enrollment":25,"indication":"Complications of Diabetes Mellitus","completionDate":"2018-07"},{"nctId":"NCT02623023","phase":"NA","title":"Brimonidine/Timolol Fixed Combination Prophylaxis for Intraocular Pressure Elevation Following Intravitreal Injection of Antivascular Endothelial Growth Factor","status":"WITHDRAWN","sponsor":"McMaster University","isPivotal":false,"enrollment":0,"indication":"Ocular Hypertension","completionDate":"2019-01-01"},{"nctId":"NCT01987752","phase":"N/A","title":"","status":"COMPLETED","sponsor":"Allergan","isPivotal":false,"enrollment":732,"indication":"Glaucoma, Open-Angle, Ocular Hypertension","completionDate":"2011-11"},{"nctId":"NCT01170884","phase":"Phase 4","title":"","status":"COMPLETED","sponsor":"Allergan","isPivotal":false,"enrollment":121,"indication":"Glaucoma, Ocular Hypertension","completionDate":"2010-09"},{"nctId":"NCT01229462","phase":"NA","title":"","status":"COMPLETED","sponsor":"Allergan","isPivotal":false,"enrollment":238,"indication":"Glaucoma, Ocular Hypertension","completionDate":"2011-09"},{"nctId":"NCT00706927","phase":"NA","title":"A Double-masked Randomized Cross-over Study Comparing of the Effect of Xalacom® (Latanoprost/Timolol)and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow","status":"COMPLETED","sponsor":"Medical University of Vienna","isPivotal":false,"enrollment":16,"indication":"Retina, Ocular Physiology","completionDate":"2010-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}